company background image
ADAP

Adaptimmune Therapeutics NasdaqGS:ADAP Stock Report

Last Price

US$1.87

Market Cap

US$306.4m

7D

1.6%

1Y

-33.2%

Updated

01 Feb, 2023

Data

Company Financials +

Adaptimmune Therapeutics plc

NasdaqGS:ADAP Stock Report

Mkt Cap: US$306.4m

ADAP Stock Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom.

ADAP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Adaptimmune Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adaptimmune Therapeutics
Historical stock prices
Current Share PriceUS$1.87
52 Week HighUS$3.32
52 Week LowUS$1.01
Beta2.18
1 Month Change28.08%
3 Month Change17.61%
1 Year Change-33.21%
3 Year Change-58.44%
5 Year Change-78.99%
Change since IPO-89.15%

Recent News & Updates

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth

Apr 15
We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth

Investors Who Bought Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Are Now Up 101%

Mar 15
Investors Who Bought Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Are Now Up 101%

Is Adaptimmune Therapeutics plc (NASDAQ:ADAP) Popular Amongst Institutions?

Feb 17
Is Adaptimmune Therapeutics plc (NASDAQ:ADAP) Popular Amongst Institutions?

Have Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insiders Been Selling Their Stock?

Jan 22
Have Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insiders Been Selling Their Stock?

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business

Jan 15
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business

Adaptimmune Therapeutics (NASDAQ:ADAP) Shareholders Have Enjoyed An Impressive 227% Share Price Gain

Dec 11
Adaptimmune Therapeutics (NASDAQ:ADAP) Shareholders Have Enjoyed An Impressive 227% Share Price Gain

Shareholder Returns

ADAPUS BiotechsUS Market
7D1.6%-0.2%1.7%
1Y-33.2%3.9%-12.5%

Return vs Industry: ADAP underperformed the US Biotechs industry which returned 1.2% over the past year.

Return vs Market: ADAP underperformed the US Market which returned -13.6% over the past year.

Price Volatility

Is ADAP's price volatile compared to industry and market?
ADAP volatility
ADAP Average Weekly Movement14.4%
Biotechs Industry Average Movement12.3%
Market Average Movement6.9%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: ADAP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ADAP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008494Ad Rawcliffehttps://www.adaptimmune.com

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company’s specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers.

Adaptimmune Therapeutics plc Fundamentals Summary

How do Adaptimmune Therapeutics's earnings and revenue compare to its market cap?
ADAP fundamental statistics
Market CapUS$306.36m
Earnings (TTM)-US$175.06m
Revenue (TTM)US$17.54m

17.5x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADAP income statement (TTM)
RevenueUS$17.54m
Cost of RevenueUS$134.18m
Gross Profit-US$116.64m
Other ExpensesUS$58.42m
Earnings-US$175.06m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin-665.12%
Net Profit Margin-998.26%
Debt/Equity Ratio0%

How did ADAP perform over the long term?

See historical performance and comparison